https://www.selleckchem.com/products/CX-3543.html
The programmed death-ligand 1 checkpoint inhibitor, atezolizumab is a monoclonal antibody that is indicated for the treatment of several cancers. Prior to administration, atezolizumab is diluted in normal saline (0.9% sodium chloride) in polyvinylchloride or polyolefin infusion bags. The objective of the studies reported in this paper was to evaluate the stability of atezolizumab diluted to 2.4 mg/mL and 9.6 mg/mL (Study 1), and 16.8 mg/mL (Study 2) in intravenous bags containing normal saline and stored for up to 12 months. Atezolizuma